Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 272 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Coronavirus reports – Part 10: “I didn’t see my mum before... September 15, 2021 New on NCI’s Websites for September 2022 September 21, 2022 Survivors of Childhood Cancer are at Excess Risk of Late Mortality... April 21, 2023 Man Walks Entire Continent To Spread Awareness About Mental Health &... January 16, 2022 Load more HOT NEWS Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... 20 years of Cancer Research UK: Celebrating our research nurses FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated...
